New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 21, 2014
10:11 EDTXNPTXenoPort urges stockholders to vote for all director nominees
XenoPort announced that it has filed a presentation with the U.S. SEC in connection with the company’s upcoming Annual Meeting, which will be held on June 11. Highlights of the presentation include: XenoPort’s Board of Directors and management team are committed to realizing the full potential of XenoPort’s assets; XenoPort’s Board is active and engaged, and has the depth, diversity of skills and expertise needed to oversee the execution of XenoPort’s strategy; XenoPort is making meaningful progress commercializing and building value in HORIZANT Extended-Release Tablets. With its focused commercial efforts involving just ~40 sales reps, XenoPort recently achieved a level of prescribed HORIZANT tablets, based on the four-week period ending May 9, that corresponds to an annualized gross demand sales run-rate of $25M; XenoPort is committed to optimizing the value of XP23829, and is taking appropriate steps to move it through the development process.
News For XNPT From The Last 14 Days
Check below for free stories on XNPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 9, 2014
08:40 EDTXNPTXenoPort, NIAAA to conduct clincial trial of Horizant ER tablets
XenoPort and the National Institute on Alcohol Abuse and Alcoholism have entered into an agreement to conduct a clinical trial of HORIZANT Extended-Release Tablets as a potential treatment for alcohol use disorder. Under the terms of the agreement, XenoPort will supply clinical trial material and the NIAAA will conduct and pay all other expenses associated with the proposed clinical trial of HORIZANT. XenoPort will have access to study results generated under the proposed clinical trial to support potential regulatory filings for HORIZANT. The study is planned to be a randomized, double-blind, placebo-controlled clinical trial of the safety and efficacy of HORIZANT in patients who have AUD but are abstinent at treatment initiation. The study is expected to have a treatment period of six months and to enroll approximately 350 patients beginning in the first half of 2015. XenoPort and the NIAAA are planning to meet with the U.S. Food and Drug Administration Division of Anesthesia, Analgesia and Addiction Products in the fourth quarter of 2014 to discuss the trial design and the possibility of utilizing the results of this trial as the basis for a potential supplemental new drug application submission for HORIZANT for the maintenance of abstinence from heavy drinking of alcohol in patients with AUD.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use